Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Sintilimab Combined With Docetaxel as Second-line Therapy in NSCLC Patients

Next Previous
Trial Profile

A Phase II Study of Sintilimab Combined With Docetaxel as Second-line Therapy in NSCLC Patients

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sintilimab (Primary) ; Docetaxel
  • Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use

Most Recent Events

  • 01 Apr 2023 Results(n=40) assessing the feasibility of sintilimab plus chemotherapy as a second-line treatment in advanced NSCLCpublished in the Journal of Cancer Research and Clinical Oncology
  • 14 Sep 2021 Updated Results of survival and safety (as of data cut-off 2/19/2021; n=40), presented at the 2021 World Conference on Lung Cancer
  • 04 Nov 2020 According to an Innovent Biologics media release, the company along with Eli Lilly announced that the data from this study will be presented during the upcoming European Society of Medical Oncology ASIA ("ESMO ASIA") Virtual Congress 2020 from November 20th to 22nd.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top